AKILI INTERACTIVE LABS
Akili Interactive Labs their broad pipeline of programs to treat cognitive deficiency and improve symptoms associated with medical conditions across neurology and psychiatry, including attention-deficit hyperactivity and disorder (ADHD), major depressive disorder (MDD), autism spectrum disorder (ASD) and various inflammatory diseases.
AKILI INTERACTIVE LABS
Industry:
Biotechnology Health Care Medical Neuroscience Service Industry Therapeutics
Founded:
2011-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.akiliinteractive.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
301.09 M USD
Technology used in webpage:
Viewport Meta SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Font Awesome Domain Not Resolving Global Site Tag
Similar Organizations
AcuraStem
AcuraStem harnesses human, patient-specific in vitro cell models and assays to develop cures and improve diagnoses in disorders of the CNS.
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
AdHawk Microsystems
AdHawk Microsystems develops camera-free eye-tracking solutions that unlock the connection between the eyes and the brain.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Neurolens
Neurolens designs prescription lenses that add a contoured prism to bring the eyes into alignment.
Freespira, Inc.
Developed the first FDA-cleared digital therapeutic that significantly reduces/eliminates symptoms of panic attacks & PTSD in only 28 days
ProMIS Neurosciences
ProMIS Neurosciences develops therapeutic products and diagnostic devices targeting misfolded protein diseases.
Revelation Biosciences
Revelation Biosciences develops immunologic therapeutics and diagnostics designed to make the world a healthier place.
Symbiotix Biotherapies
Symbiotix Biotherapies is a provider of a novel class of molecular therapeutics intended to develop molecules.
UNITY Biotechnology
Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Fearless Ventures
Fearless Ventures investment in Series D - Akili Interactive Labs
Omidyar Technology Ventures
Omidyar Technology Ventures investment in Series D - Akili Interactive Labs
Shionogi
Shionogi investment in Series D - Akili Interactive Labs
QUAD Investment Management
QUAD Investment Management investment in Series D - Akili Interactive Labs
Jazz Venture Partners
Jazz Venture Partners investment in Series D - Akili Interactive Labs
M Ventures
M Ventures investment in Series D - Akili Interactive Labs
Neuberger Berman Group
Neuberger Berman Group investment in Series D - Akili Interactive Labs
David Baszucki
David Baszucki investment in Series D - Akili Interactive Labs
Mirae Asset Global Investments
Mirae Asset Global Investments investment in Series D - Akili Interactive Labs
Evidity Health Capital
Evidity Health Capital investment in Series D - Akili Interactive Labs
Newest Events participated
Key Employee Changes
Date | New article |
---|---|
2022-06-06 | Akili Announces Veteran Life Sciences Executive Matt Franklin in Newly Created Role of President and Chief Operating Officer |
Official Site Inspections
http://www.akiliinteractive.com Semrush global rank: 1.25 M Semrush visits lastest month: 23.98 K
- Host name: 198.49.23.145
- IP address: 198.49.23.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013